Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.
about
Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma.Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosisSuppressed rate of carcinogenesis and decreases in tumour volume and lung metastasis in CXCL14/BRAK transgenic mice.Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell CancerChemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection.A New Strategy to Find Targets for Anticancer Therapy: Chemokine CXCL14/BRAK Is a Multifunctional Tumor Suppressor for Head and Neck Squamous Cell Carcinoma.A striking local esophageal cytokine expression profile in eosinophilic esophagitis.Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell transplants. [corrected]Expression of tumour-suppressing chemokine BRAK/CXCL14 reduces cell migration rate of HSC-3 tongue carcinoma cells and stimulates attachment to collagen and formation of elongated focal adhesions in vitro.The epigenetic regulation of CXCL14 plays a role in the pathobiology of oral cancersHeterozygous mutation (G/G→G/A) at nt 2607 of the EGFR gene is closely associated with increases in EGFR copy number and mRNA half life, but impaired EGFR protein synthesis in squamous cell carcinomas of the head and neck - implication for gefitinibCXCL14-like Immunoreactivity Exists in Somatostatin-containing Endocrine Cells, and in the Lamina Propria and Submucosal Somatostatinergic Nervous System of Mouse Alimentary Tract.
P2860
Q33586751-F431625D-A5E7-42C6-BFAD-BCCD328744B3Q34134446-A7760F61-1216-45B1-B639-0E488AD2738BQ35172310-466E4C7F-EB74-43BE-A752-2682A4B588F2Q35875753-22344BE5-6A37-4348-A13D-814ADD9D3E1CQ36552786-819015D9-AE35-4CB7-8B43-D0E8AF02AFB8Q36900220-63E9B1D1-3B13-4D3C-A06F-0175773B155EQ38338212-A5E28512-4332-45A4-8966-05286C8AB385Q39723710-9D9FC715-5319-4F8B-A41B-4AE6CE766F19Q39753202-38B446EE-E6E0-47DB-A011-4D746221010AQ41721652-AB33D9F1-32B1-4DB0-9FBA-A88D0245A7E6Q42227138-620B3FFD-F7E7-424F-9589-AC96843E3A14Q47855315-5330EB53-EF4B-4B3C-BD5F-240027D01647
P2860
Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Restoration of BRAK / CXCL14 g ...... neck squamous cell carcinoma.
@en
Restoration of BRAK / CXCL14 g ...... neck squamous cell carcinoma.
@nl
type
label
Restoration of BRAK / CXCL14 g ...... neck squamous cell carcinoma.
@en
Restoration of BRAK / CXCL14 g ...... neck squamous cell carcinoma.
@nl
prefLabel
Restoration of BRAK / CXCL14 g ...... neck squamous cell carcinoma.
@en
Restoration of BRAK / CXCL14 g ...... neck squamous cell carcinoma.
@nl
P2093
P2860
P1433
P1476
Restoration of BRAK / CXCL14 g ...... neck squamous cell carcinoma.
@en
P2093
Eiro Kubota
Keiichi Tsukinoki
Mamoru Tsukuda
Naoto Shiiki
Reika Komori
Ryu-Ichiro Hata
Satoru Ozono
Shigeyuki Ozawa
Takahide Taguchi
P2860
P304
P356
10.1111/J.1349-7006.2009.01281.X
P577
2009-08-08T00:00:00Z